Oasmia Pharmaceutical AB (publ)
Interim report for the period May - October 2012 €
THE MARKET AUTHORIZATION PROCESS FOR PACLICAL® HAS BEGUN
THE PERIOD May 1 – October 31, 2012
- Consolidated Net sales amounted to € 0 thousand (103) [1]
- Operating income amounted to € -3,627 thousand (-3,336)
- Net income after tax amounted to € -3,932 thousand (-3,329)
- Earnings per share amounted to € -0.07 (-0.06)
- Comprehensive income amounted to € -3,932 thousand (-3,329)
SECOND QUARTER August 1 – October 31, 2012
- Consolidated Net sales amounted to € 0 thousand (0)
- Operating income amounted to € -1,501 thousand (-1,553)
- Net income after tax amounted to € -1,690 thousand (-1,559)
- Earnings per share amounted to € -0.03 (-0.03)
- Comprehensive income amounted to € -1,690 thousand (-1,559)
-
Oasmia has initiated the market authorization process for Paclical® with Russia as the first country of submission.
-
Oasmia initiates collaboration with Pharmasyntez in Russia
- The company announces fully underwritten preferential rights share issue of SEK 123 million
EVENTS AFTER CLOSING DAY
- The rights issue is completed
[1] The numbers in parentheses concern results from the corresponding period of the previous year
Johan Edin, acting Head of PR & Communications +46 18 50 54 40 press@oasmia.com, www.oasmia.com
